DexCom, Inc. (NASDAQ:DXCM) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of DexCom, Inc. (NASDAQ:DXCM) have been assigned an average recommendation of “Moderate Buy” from the fourteen ratings firms that are currently covering the firm, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $141.67.

Several research firms recently weighed in on DXCM. Canaccord Genuity Group raised their target price on shares of DexCom from $144.00 to $145.00 and gave the company a “buy” rating in a research note on Friday, April 26th. Citigroup boosted their price objective on shares of DexCom from $148.00 to $161.00 and gave the stock a “buy” rating in a research note on Wednesday, April 3rd. StockNews.com upgraded shares of DexCom from a “hold” rating to a “buy” rating in a research note on Wednesday, May 1st. Raymond James boosted their price target on DexCom from $151.00 to $160.00 and gave the stock a “strong-buy” rating in a research report on Friday, April 26th. Finally, Royal Bank of Canada started coverage on DexCom in a research report on Tuesday, March 12th. They issued an “outperform” rating and a $165.00 price objective for the company.

Insider Buying and Selling

In other DexCom news, EVP Michael Jon Brown sold 629 shares of the stock in a transaction that occurred on Tuesday, April 30th. The shares were sold at an average price of $126.25, for a total transaction of $79,411.25. Following the transaction, the executive vice president now owns 68,212 shares in the company, valued at approximately $8,611,765. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other DexCom news, EVP Michael Jon Brown sold 629 shares of DexCom stock in a transaction on Tuesday, April 30th. The stock was sold at an average price of $126.25, for a total value of $79,411.25. Following the completion of the transaction, the executive vice president now directly owns 68,212 shares of the company’s stock, valued at approximately $8,611,765. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Sadie Stern sold 4,137 shares of the firm’s stock in a transaction on Monday, March 25th. The stock was sold at an average price of $140.00, for a total value of $579,180.00. Following the completion of the transaction, the executive vice president now owns 76,304 shares in the company, valued at approximately $10,682,560. The disclosure for this sale can be found here. Over the last three months, insiders have sold 190,004 shares of company stock valued at $25,610,270. 0.41% of the stock is owned by company insiders.

Institutional Trading of DexCom

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Team Hewins LLC increased its position in shares of DexCom by 3.4% during the first quarter. Team Hewins LLC now owns 2,555 shares of the medical device company’s stock worth $354,000 after buying an additional 83 shares during the period. Stableford Capital II LLC grew its holdings in DexCom by 2.1% during the 4th quarter. Stableford Capital II LLC now owns 4,367 shares of the medical device company’s stock worth $563,000 after acquiring an additional 88 shares during the period. D Orazio & Associates Inc. raised its position in shares of DexCom by 0.8% in the 4th quarter. D Orazio & Associates Inc. now owns 12,366 shares of the medical device company’s stock worth $1,534,000 after acquiring an additional 93 shares in the last quarter. Gulf International Bank UK Ltd lifted its stake in shares of DexCom by 0.3% in the 1st quarter. Gulf International Bank UK Ltd now owns 32,075 shares of the medical device company’s stock valued at $4,448,000 after purchasing an additional 93 shares during the period. Finally, EverSource Wealth Advisors LLC boosted its position in shares of DexCom by 10.1% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,071 shares of the medical device company’s stock valued at $133,000 after purchasing an additional 98 shares in the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.

DexCom Trading Up 0.3 %

DexCom stock opened at $130.10 on Friday. The company has a market cap of $51.74 billion, a price-to-earnings ratio of 83.94, a P/E/G ratio of 2.19 and a beta of 1.23. The firm has a 50-day moving average of $132.67 and a 200-day moving average of $121.11. The company has a debt-to-equity ratio of 1.08, a current ratio of 2.90 and a quick ratio of 2.53. DexCom has a one year low of $74.75 and a one year high of $142.00.

DexCom (NASDAQ:DXCM) last released its earnings results on Thursday, April 25th. The medical device company reported $0.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.27 by $0.05. The business had revenue of $921.00 million for the quarter, compared to analyst estimates of $911.20 million. DexCom had a return on equity of 31.01% and a net margin of 16.82%. On average, equities analysts expect that DexCom will post 1.78 earnings per share for the current fiscal year.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.